Facebook
Twitter
LinkedIn
Forward
OMA 2023 Spring Summit: Overcoming Barriers to Initiating Anti-Obesity Medications (On Demand)CME/CE Expiration Date: 4/23/26
|
Obesity is a disease that disproportionately affects women. Those from ethnic/racial minorities and those who live in poverty are often more severely affected.
|
In this session, speaker will deliver current endocrine society guidelines on gender affirming therapies and the association of obesity with high dose reproductive hormone initiation.
|
A core component of obesity treatment includes recognition of weight promoting medications and their alternatives.
|
Alicia Shelly, MD will discuss the prevalence and etiologies of weight regain after bariatric surgery.
|
This presentation will provide an overview of the evidence basis for using continuous glucose monitoring (CGM) in patients with obesity.
|
The challenges of treating co-morbid binge eating disorder and obesity".
|
This session will focus on the management of non-alcoholic fatty liver disease (NAFLD) with a particular emphasis on the role of GLP-1 agonists and SGLT-2 inhibitors in treating this condition.
|
Weight stigma is an often-overlooked contributor to poor patient engagement and weight gain over time.
|
This roundtable discussion covers metabolic bariatric surgery in children and adolescents based on the 2018 ASMBS pediatric metabolic and bariatric surgery guidelines.
|